Danese Silvio Professore OrdinarioMedicinaMED/12
Silvio Danese is a Gastroenterologist and Professor of Gastroenterology at Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy, since October 2021, where he is Head Gastroenterology and Gastrointestinal Endoscopy Unit.
Before that, Prof Danese was Head of IBD Centre and ImmunoCentre at IRCCS Humanitas, Rozzano, Milan, Italy, and Professor of Gastroenterology at Humanitas University.
Silvio Danese trained in Gastroenterology at Policlinico Gemelli, Rome and graduated as a PhD, working from 2001 to 2004 in Dr. Claudio Fiocchi’s laboratory at the Case Western Reserve University, Cleveland, Ohio, USA.
His main research area of interest is the investigation of the fundamental mechanisms underlying IBD pathogenesis, while his daily clinical activity is related to IBD service. He is actively involved in many international clinical trials in IBD and has published more than 700 papers in several journals, including New England Journal of Medicine, Lancet, Gastroenterology, Gut, Journal of Clinical Investigation.
He is a member of many organizations related to the IBD field, including the European Crohn´s and Colitis Organization (ECCO), where he is Past President (2018 – 2020).
ORCID ID: https://orcid.org/0000-0001-7341-1351
EDUCATION AND TRAINING
1999 Degree in Medicine, Catholic University School of Medicine, “A. Gemelli” Hospital, Rome, Italy, 110/110 Cum Laude
1993 High School Diploma in Scientific Studies, Liceo Scientifico Galileo Galilei, Potenza, 60/60
2003 Residency in Gastroenterology, Residency Program in Gastroenterology, Catholic University School of Medicine, Rome, Italy, 70/70 Cum Laude
2013 Full Professor of Gastroenterology (Professore Ordinario), National Scientific Habilitation, Italy
2013 Full Professor of Internal Medicine (Professore Ordinario), National Scientific Habilitation, Italy
2004 PhD in Metabolism, Catholic University School of Medicine, Rome, Italy
2001 – 2002 Post-doctoral fellowship, Case Western Reserve University, Cleveland, Ohio, USA
2002 – 2004 Research Associate, Case Western Reserve University, Cleveland, Ohio, USA
2021 – present Full Professor of Gastroenterology, Vita-Salute San Raffaele University, Milano, Italy
2015 – 2021 Full Professor of Gastroenterology, Humanitas University, Rozzano, Milano, Italy
2015 – 2020 Director, Residency Program of Gastroenterology, Humanitas University, Rozzano, Milano, Italy
2019 – present Faculty Member, PhD Program in MOLECULAR AND EXPERIMENTAL MEDICINE, Humanitas University, Rozzano, Milano, Italy
2007 – 2014 Teacher, School of Medicine of Università degli Studi di Milano, Milano, Italy CLINICAL
2021 – present Director, Gastroenterology and Gastrointestinal Endoscopy Unit Istituto Clinico San Raffaele, Milano
2016 – 2021 Director, Immunocenter, (IBD, Rheumatology, Dermatology) Istituto Clinico Humanitas, Rozzano, Milano
2008 – 2021 Head, IBD Center, Department of Gastroenterology, Istituto Clinico Humanitas, Rozzano, Milano
2006 – 2008 Staff member, Gastroenterology Unit, Department of Gastroenterology, Istituto Clinico Humanitas, Rozzano, Milano
THE LAST GRENTS
· 5 years grant from European Community on Immune mediate diseases. Work package coordinator. (400.000 Euro) (2011)
·4 years grant from NIH for the project: The lymphatic system in Inflammatory bowel disease (1.000.000 US $) (2011)
· 2 years Grant from The Broad Foundation for the project: The role of Triggered Receptor Expressed on Myeloid cell-2 (TREM-2) and intestinal flora in colon cancer development (220.000 Euro) (2012)
· 3 years Grant from AIRC for the project: The role of Triggered Receptor Expressed on Myeloid cell-2 (TREM-2) and intestinal flora in colon cancer development (360.000 Euro) (2013)
· 3 years Grant from the Italian Ministery of Health for the project: New cellular and molecular mechanisms in Colitis-Associated Colorectal Cancer: implications for innovative therapeutic approaches (450.000 Euro) (2013)
· 4 years Grant from Italian Ministery of Health (FIRB-Futuro in Ricerca) for the project: New cellular and molecular mechanisms in Colitis-Associated Colorectal Cancer: implications for innovative therapeutic approaches (448.000 Euro) (2013)
· 2 years Grant from Humanitas Research Hospital for the project: The role of TREM-2 in IBD pathogenesis: implications for novel therapeutic approaches (100.000 Euro) (2014)
· 3 years Grant from AIRC for the project: Role of TRPV-4 in the pathogenesis of Colorectal Cancer (450.000 Euro) (2017)
· 2 years Grant from the Broad Medical Research Program for the project: Resolution of IBD by promoting endogenous lipid-mediated pro-resolving pathways: a novel approach to pathogenesis and therapy (140.800 Euro) (2017)
· Coordinator of a 5 year Grant from the Horizon 2020, H2020-JTI-IMI2-2018-15 IMI, Innovative Medicines Initiative 2 for the ImmUniverse project: Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies (15,5 millions Euro) (2020) · Coordinator of a
3 years grant from EURONANOMED III for the project: Gut-targeted RNAbased nanoparticles for fibrostenotic Crohn’s Disease: a novel therapeutic approach (1 million Euro) (2020)
Publications: n 693 (please, be aware that in PubMed there are some hits duplicates because of corrections due to mistakes in the affiliation of some authors)
Metrics: Total Impact Factor: 6367,578
Citations: 34670 (Scopus); 47614 (Google Scholar)
H index: 92 (Scopus); 106 (Google Scholar)
i-10 index: 498 (Google Scholar)
Short Narrative: 2021
Spinelli A, Carvello M, Adamina M, Panis Y, Warusavitarne J, Tulchinsky H,
Bemelman WA, Kotze PG, D'Hoore A, Lastikova L, Danese S, Peyrin-Biroulet L, Avedano
L, Pagnini F.
Patients' perceptions of surgery for inflammatory bowel disease.
Colorectal Dis. 2021 Jul 16. doi: 10.1111/codi.15813. Online ahead of print. (IF 2020:
Carvello M, Bellato V, Maroli A, Hart A, Danese S, Warusavitarne J, Spinelli A.
A multidisciplinary approach to rectal cancer treatment in ulcerative colitis results in high
rate of restorative minimally invasive surgery.
J Crohns Colitis. 2021 Aug 4:jjab139. doi: 10.1093/ecco-jcc/jjab139. Online ahead of print.
(IF 2020: 9,071)
Furfaro F, Dal Buono A, Allocca M, D'Amico F, Zilli A, Gabbiadini R, Danese S.
Bowel Ultrasound in Inflammatory Bowel Disease: How Far in the Grayscale?
Life (Basel). 2021 Jul 4;11(7):649. doi: 10.3390/life11070649. (IF 2020: 3,817)
Craviotto V, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Fiorino G, Danese S,
Viral infections in inflammatory bowel disease: Tips and tricks for correct management.
World J Gastroenterol. 2021 Jul 21;27(27):4276-4297. doi: 10.3748/wjg.v27.i27.4276. (IF
Fiorino G, Allocca M, Danese S.
Adalimumab biosimilar in inflammatory bowel disease.
Lancet Gastroenterol Hepatol. 2021 Oct;6(10):775-776. doi: 10.1016/S2468-
1253(21)00266-1. Epub 2021 Aug 11. (IF 2020: 18,486)
Caron B, D'Amico F, Danese S, Peyrin-Biroulet L.
Cluster Randomized Trials: Lessons for Inflammatory Bowel Disease Trials.
J Crohns Colitis. 2021 Aug 14:jjab149. doi: 10.1093/ecco-jcc/jjab149. Online ahead of
print. (IF 2020: 9,071)
Vermeire S, D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV Jr, Bhatia S,
Agboton C, Rosario M, Chen C, Zhang W, Kisfalvi K, Sandborn WJ.
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely
Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.
J Crohns Colitis. 2021 Aug 17:jjab133. doi: 10.1093/ecco-jcc/jjab133. Online ahead of
print. (IF 2020: 9,071)
Hassan-Zahraee M, Ye Z, Xi L, Baniecki ML, Li X, Hyde CL, Zhang J, Raha N,
Karlsson F, Quan J, Ziemek D, Neelakantan S, Lepsy C, Allegretti JR, Romatowski J, Scherl
EJ, Klopocka M, Danese S, Chandra DE, Schoenbeck U, Vincent MS, Longman R, Hung
Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and
Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.
Inflamm Bowel Dis. 2021 Aug 24:izab193. doi: 10.1093/ibd/izab193. Online ahead of print.
(IF 2020: 5,325)
Solitano V, Parigi TL, Ragaini E, Danese S.
Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into
Expert Opin Investig Drugs. 2021 Sep 6:1-10. doi: 10.1080/13543784.2021.1974396.
Online ahead of print. (IF 2020: 6,206)
Olivera PA, Zuily S, Kotze PG, Regnault V, Al Awadhi S, Bossuyt P, Gearry RB,
Ghosh S, Kobayashi T, Lacolley P, Louis E, Magro F, Ng SC, Papa A, Raine T, Teixeira
FV, Rubin DT, Danese S, Peyrin-Biroulet L.
International consensus on the prevention of venous and arterial thrombotic events in
patients with inflammatory bowel disease.
Nat Rev Gastroenterol Hepatol. 2021 Aug 27:1-17. doi: 10.1038/s41575-021-00492-8.
Online ahead of print. (IF 2020: 46,802)
Sandborn W, Mattheakis LC, Modi NB, Pugatch D, Bressler B, Lee S, Bhandari R,
Kanwar B, Shames R, D'Haens G, Schreiber S, Danese S, Feagan B, Pai RK, Liu DY, Gupta
PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a
Studies in Ulcerative Colitis.
Gastroenterology. 2021 Aug 30:S0016-5085(21)03463-6. doi:
10.1053/j.gastro.2021.08.045. Online ahead of print. (IF 2020: 22,682)
Norsa L, Bonaffini PA, Caldato M, Bonifacio C, Sonzogni A, Indriolo A, Valle C,
Furfaro F, Bonanomi A, Franco PN, Gori M, Smania V, Scaramella L, Forzenigo L, Vecchi
M, Solbiati M, Costantino G, Danese S, D'Antiga L, Sironi S, Elli L.
Intestinal ischemic manifestations of SARS-CoV-2: Results from the ABDOCOVID
World J Gastroenterol. 2021 Aug 28;27(32):5448-5459. doi: 10.3748/wjg.v27.i32.5448. (IF
Tursi A, Nenna R, Danese S.
Therapeutic Response to Adalimumab in a Case of Steroid-Dependent Segmental Colitis
Associated With Diverticulosis.
Am J Gastroenterol. 2021 Aug 1;116(8):1760-1761. doi: 10.14309/ajg.0000000000001226.
(IF 2020: 10,864)
Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh
S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L,
Danese S; True North Study Group.
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617. (IF 2020:
Schwartz DA, Peyrin-Biroulet L, Lasch K, Adsul S, Danese S.
Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing
Crohn's Disease: ENTERPRISE Study.
Clin Gastroenterol Hepatol. 2021 Sep 28:S1542-3565(21)01042-9. doi:
10.1016/j.cgh.2021.09.028. Online ahead of print. (IF 2020: 11,382)
Caron B, Netter P, Danese S, Peyrin-Biroulet L.
Bispecific antibodies for the treatment in inflammatory bowel disease: an avenue worth
Expert Opin Biol Ther. 2021 Oct 6. doi: 10.1080/14712598.2022.1985999. Online ahead of
print. (IF 2020: 4,388)
Il titolare del presente curriculum vitae, pubblicato online sul portale www.unisr.it, è garante in via esclusiva della correttezza e della veridicità dei dati e delle informazioni in esso riportate e del loro eventuale e puntuale aggiornamento. Egli è dunque il diretto ed unico responsabile dei contenuti indicati nei propri curricula.